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Abstract: The third-generation bovine pericardium Freedom SOLO (FS) stentless valve emerged 
in 2004 as a modified version of the Pericarbon Freedom stentless valve and as a very attractive 
alternative to stented bioprostheses. The design, choice of tissue, and anticalcification treatment 
fulfill most, if not all, requirements for an ideal valve substitute. The FS combines the single-
suture, subcoronary implantation technique with the latest-generation bovine pericardial tissue 
and novel anticalcification treatment. The design allows imitation of the native healthy valve 
through unrestricted adaption to the patient’s anatomy, reproducing a normal valve/root complex. 
However, despite hemodynamic performance superior to stented valves, we are approaching a 
critical observation period as superior durability, freedom from structural valve deterioration, 
and nonstructural failure has not been proven as expected. However, optimal performance and 
freedom from structural valve deterioration depend on correct sizing and perfect symmetric 
implantation, to ensure low leaflet stress. Any malpositioning can lead to tissue fatigue over 
time. Furthermore, the potential for better outcomes depends on optimal patient selection and 
observance of the limitations for the use of stentless valves, particularly for the FS. Clearly, stent-
less valve implantation techniques are less reproducible and standardized, and require surgeon-
dependent experience and skill. Regardless of whether or not stentless valve durability surpasses 
third-generation stented bioprostheses, they will continue to play a role in the surgical repertoire. 
This review intends to help practitioners avoid pitfalls, observe limitations, and improve patient 
selection for optimal long-term outcome with the attractive FS stentless valve.
Keywords: aortic valve, bioprosthesis, cardiac surgery, aortic valve replacement, tissue valve, 
stentless aortic valve, hemodynamics, long-term results
Background
Aortic valve prostheses have evolved considerably over the last 50 years, especially with 
respect to technical aspects, such as design, implantation technique, and processing. 
Treatment of aortic valve pathologies with valve prostheses began with the use of 
cage-ball valves in the descending aorta of patients with aortic regurgitation.1 This 
was followed by subcoronary aortic valve replacement (AVR) using aortic allografts 
(homografts),2,3 and mechanical cage-ball and “monostrut” models in the 1960s.4 
Interestingly, homografts mounted on a stented frame were used as early as in 1965, 
to simplify implantation techniques; however, these stents caused tissue failure within 
a few years and as such, were less durable than freehand-sewn homografts and were 
subsequently abandoned.5
Stent-mounted porcine xenograft valves, first implanted in 1964 and 1965,6,7 were 
treated with mercurial solution and formaldehyde8 in order to arrest autolysis and 
fix tissue, but this treatment also caused shrinkage and stiffness. The introduction 
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of  glutaraldehyde (GA) fixation9 represents the next major 
advance and is still used today for all bioprostheses. However, 
the high rate of early mechanical failure with first-generation 
stented porcine xenografts10 soon became obvious, particu-
larly in younger patients and thus stimulated work to improve 
preservation, biocompatibility, design, and valve mounting 
strategies.11
Conceptually, the ideal valve substitute has remained 
largely unchanged12 and includes unobstructed central flow, 
maximum effective orifice area (EOA) with low transvalvular 
gradients, low thrombogenicity, prolonged durability, easy 
implantability, resistance to infection, and freedom from anti-
coagulation.13 However, still today, no single prosthesis fulfils 
all of these criteria. Widespread use of homografts is limited 
by the practical problems of restricted availability of different 
sized specimens, demanding techniques, and questionable 
long-term outcomes, while mechanical valves still require 
lifelong anticoagulation with the potential of undesirable 
secondary events. Following the observation of significantly 
lower valve leaflet deterioration in homografts compared with 
(first-generation) stented xenografts,14 the stentless valve 
concept was proposed to combine the advantages of both 
homografts (nonobstructive EOA) and stented bioprostheses 
(unlimited availability). Furthermore, a flexible aortic root 
was believed to be essential for natural leaflet stress distri-
bution; thus, implantation of an unstented xenograft with 
minimal disruption of aortic root dynamics was expected to 
reduce dynamic stress on leaflets, thereby translating into a 
lower probability of structural valve deterioration (SVD).15 
In addition, the importance of left ventricular (LV) mass was 
identified in the Framingham Heart Study,16 and complete 
regression of LV hypertrophy (LVH) was defined as a major 
prognostic factor determining late outcome after AVR.17 
Importantly, the stentless design was expected to better permit 
regression as a result of superior hemodynamics due to lower 
gradients in the absence of obstructive stents.
The current review describes the Freedom SOLO (FS) 
stentless valve (Sorin Biomedica, Saluggia, Italy), a valve 
that was introduced in our teaching institution in 2004 
because the implantation was thought to be easy and hemo-
dynamic performance was expected to be favorable.
Evolution of the FS stentless valve
The FS is directly derived from the Pericarbon Freedom (PF) 
stentless (Sorin Biomedica), which has been available since 
1991.18 Cusp shaping and tissue fixation of the PF is obtained 
with a fluidic process that uses increasing GA  concentrations 
(up to 0.5%) in phosphate buffer at pH 7.4 under low 
 pressure.19 The PF was redesigned in 2000 with the  addition 
of a posttreatment step using homocysteic acid (HCA) in 
order to remove aldehyde residues, as further discussed 
below. The resulting two-sheet structure is composed of an 
external scalloped cylinder containing an internal cylinder 
in the form of three valvular cusps, and the inflow rim. This 
design avoids the stitches becoming points of excessive stress 
concentration – where fatigue fracture lines would eventu-
ally originate – particularly, in the commissural areas.18 The 
PF bioprosthesis is provided by the manufacturer with extra 
tissue, allowing intraoperative tailoring for adaptation to the 
patient’s specific anatomy and the surgeon’s technique, and 
is implanted with two suture lines (Figure 1A).
The FS bovine pericardial aortic valve emerged in 
May 2004 as a modified version of the PF valve (Figure 1B). 
The design modification that resulted in the FS was aimed at 
allowing subcoronary, supra-annular implantation with only 
one suture line, achieved through the trimming of all extra 
tissue from the PF valve inflow side, and the scalloping of the 
outflow side to preserve the valve assembly suture.20 As such, 
the FS combines the latest-generation bovine pericardial 
tissue and novel anticalcification treatment, with the single-
suture, subcoronary implantation technique first applied by 
O’Brien to porcine stentless valves.21 This design allows 
imitation of the native healthy valve through unrestricted 
adaption to each individual patient’s anatomy.
Finally, the prosthesis holder was recently replaced with 
a short metal stent holder for easier handling (Figure 1C), 
indicated by the addition of “Smart” to the valve’s name.
Implantation technique of the FS: 
tips and pitfalls
When the implantation of a FS stentless valve is planned, 
a transverse aortotomy should be performed high above the 
commissures, in order to provide good vision over the sinuses 
as well as sufficient space for FS commissure attachment to 
the aortic wall. Three reference “stay” sutures placed slightly 
above the commissures are helpful. Particular attention 
must be paid to the aortic root anatomy, and a correct sizing 
is  critical. Symmetric implantation may be difficult with a 
Figure 1 Pericarbon Freedom (A), Freedom SOLO (B), and SOLO Smart (C).
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wide and deep noncoronary (NC) sinus and particularly in the 
case of bicuspid aortic valve (BAV), when the commissure 
landmark is missing. We therefore discourage use of a stent-
less valve in a BAV root anatomy. There is also a potential risk 
of regurgitation over time, due to presumed coexistent aortic 
disease and potentially later aortic dilatation in these patients. 
The use of FS should therefore be avoided in patients with 
BAV and in those with moderate dilatation of the ascending 
aorta. The fundamental importance of accurate sizing and 
prosthesis selection must be emphasized. The probe should 
tightly fit the aortic annulus (Figure 2A). The prosthetic valve 
corresponding to the probe is already upsized by the manu-
facturer, to one size more or 2 mm larger than the annular 
diameter. When in doubt with determining the correct valve 
size, one should consider that oversizing the FS may result 
in S-shaped leaflet folding with functional stenosis and high 
gradients.22 Another source of dysfunction can be the presence 
or likelihood of future root and/or sinotubular junction dilata-
tion, which have the potential to cause  regurgitation.23 This 
means that both oversizing and undersizing have the potential 
to cause prosthesis failure. In general, if one size is too small 
and the larger one fits the annulus with some resistance, the 
larger one should be implanted.24
Three equidistant, intercommissural sutures (polypro-
pylene 4-0, using a small taper-cut semicircular needle) 
are then placed in the supra-annular position at the nadir of 
each sinus, at 2–3 mm above the native annulus. Each of 
these sutures must be placed at the corresponding part of the 
 tissue valve cusps, using the pericardial strip available at the 
basis of the stentless valve (Figure 2B). Placement of sutures 
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Figure 2 implantation technique of the Freedom SOLO stentless valve.
Notes: (A) Transverse aortotomy, 3 string sutures at the level of the commissures and sizing. (B) The first three stitches are passed at the nadir of each sinus and through 
the pericardial rim of the tissue valve. (C) The valve is parachuted down into the aortic anulus. (D) The first stitch is demonstrated at the nadir of the sinus. (E) The 
continuous suture is performed in direction of the commissure. (F) This picture demonstrates the sequence of suturing the tissue valve. Starting below the right coronary 
artery and moving to both commissures (1, 2, and 4) then below the left coronary artery (3 and 5) and finally suturing the non-coronary leaflet at the end (6 and 7). A, 
right-coronary cusp; B, left-coronary cusp; C, non-coronary cusp. (G) Tying of the sutures is performed outside the aorta at the level of the three commissures. (H) Final 
view of the supraanular, subcoronary continuous suture line from inside the aorta. (I) Final view from outside the aorta with demonstration of a maximized central and 
homogeneous flow through the valve.
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below or through the annulus must be avoided. At the level 
of the commissures, the sutures are passed out of the aorta 
and tied together (Figure 2C–E). At the end of the suturing 
process, the FS becomes somewhat fixed in the aortic root 
and the exposition may be more difficult, potentially making 
suturing difficult, especially in cases with small valve sizes. 
It is important to avoid too small suture bites, to prevent 
dehiscence. Care must be taken to avoid any laceration of 
the valve leaflets with a needle tip and also to prevent any 
damage of the assembly suture of the valve. Some surgeons 
have suggested to start suturing at the right coronary sinus, 
followed by the left coronary sinus, and finally the NC sinus,20 
but in fact, any order can be followed25 (Figure 2F). There 
is large individual variability in root anatomy, and the NC 
sinus often presents wider and deeper than the symmetric 
prosthesis. Therefore, the suture line can be longer, and 
consequently, relatively less valve tissue might be available 
for a longer distance between commissures, resulting in 
bites that create folding or tension.25 In fact, most reported 
failures and thrombosis were thought to be associated with 
the NC cusp.26,27 In the NC sinus, the suturing plane should 
be intentionally elevated by 1–2 mm, but care must be taken 
to follow the annular line (and not to create a straight line). 
It was also suggested to begin suturing the NC sinus by 
applying only the first 2–3 stitches on each side, in order to 
assure tension-free seating of the prosthesis on a nonwrinkled 
aortic sinus under perfect exposure, and then to continue with 
the right and left sinus, and finally complete the NC sinus 
suture line.25 In our opinion, the key is to perform correct and 
tension-free sutures comfortably, regardless of the sequence. 
We have made it routine to check for folding and leaks with 
a small instrument (nerve hook). Additional stitches to cor-
rect for folding or suspected leaks can be made through the 
prosthesis and with the knot tied outside the aorta.
Postoperative anticoagulation 
management
According to our patient management protocol, if there is no 
bleeding, patients receive intravenous unfractionated heparin 
to obtain a partial thromboplastin time of 60 seconds.  Heparin 
was replaced with subcutaneous weight-adapted enoxaparin on 
the second or third postoperative day. Because of reported FS-
associated thrombocytopenia, platelet numbers were recorded 
daily during the hospital stay. Usually after the fourth postopera-
tive day and following mobilization of the patient, antiplatelet 
therapy, with acetylsalicylate 100 mg daily, is instituted. As 
standard protocol, only patients with preoperative cardiomyo-
pathy, chronic atrial fibrillation, or peripheral occlusive vascular 
disease continued with warfarin (Marcoumar®). Patients who 
have isolated AVR combined with coronary artery bypass graft-
ing (CABG) continued with acetylsalicylate only.
Tissue fixation and anticalcification 
treatment
All biological tissue valves undergo chemical fixation with 
GA to provide mechanical stability; this is at the expense of 
greater susceptibility to calcification, via increases in cal-
cium binding sites, namely, GA residues and phospholipid 
debris.28 In an exclusive treatment, Sorin uses HCA, which 
features strong electronegative sulfonic groups as postfixation 
treatment and which cross-links GA to neutralize the free 
toxic aldehyde groups.20,29 The valve is stored in paraben 
(antimycotic) solution and yields a ready-to-use prosthetic 
valve that does not require rinsing prior to implantation. The 
detoxification efficacy is tested by measuring free aldehyde 
groups and by in vitro cultivation of human endothelial cells 
on pericardial samples. Detoxified samples (with HCA) 
showed negligible GA residues and improved endothelial 
cells proliferation compared with conventionally treated 
samples, whereas tissue fatigue behavior was not modified 
by HCA treatment.19 Mineralization is usually tested through 
subcutaneous or intramuscular implantation of valve tissue 
into animals (rats or rabbits) with determination of calcifica-
tion, after explantation, using light transmission and scanning 
electron microscopy as well as atomic absorption spec-
troscopy. In the subcutaneous rat model, GA-HCA-treated 
bovine pericardium showed less calcification than did GA 
alone, after explantation (performed between days 14–84).29 
However, the effectiveness of this testing has been questioned 
because this model ignores mechanical and dynamic stress 
as well as blood–surface contact.30 In fact, results from the 
subcutaneous rat model are completely opposite to those 
obtained in blood pulsatile models, thereby emphasizing the 
necessity of blood contact in preclinical valve testing.30
Patient selection
The ideal patient for FS tissue valve implantation is older 
than 65 years, and has a symmetric aortic root and a trileaflet 
valve-sinus anatomy. Younger and active patients wishing to 
avoid anticoagulation and a mechanical valve, and those for 
whom a homograft is not available may also be candidates. 
In addition, the FS stentless valve is a very attractive alter-
native prosthesis for patients with active endocarditis. The 
supra-annular fixation spares impaired subannular inflam-
matory tissue and septal abscesses. Indeed, stentless valve 
prostheses were found to be  associated with low reinfection 
rates and excellent hemodynamic performance comparable 
with cryopreserved homografts.31 Patients with BAV must 
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Table 1 Patient characteristics and operative data
Total AVR  
isolated
AVR  
combined
N 423 226 197
Age (years) 74.0±7.8  
(40.9–90.5)
73.4±8.3  
(41.0–90.5)
74.6±7.2  
(40.9–90.3)
Sex
 Male 216 (51.1%) 105 (46.5%) 111 (56.4%)
 Female 207 (48.9%) 121 (53.5%) 86 (43.6%)
BMi (kg/m2) 27.6±4.6  
(16.9–46.3)
28.0±4.8  
(19.2–46.3)
27.1±4.2  
(1.38–2.33)
BSA (Dubois) m2 1.86±0.21  
(1.27–2.56)
1.87±0.21  
(1.27–2.56)
1.84±0.20  
(19.2–46.2)
LveF% 56±11 57±10 55±13
Log STS-euroScore 10.24±10.49 
 (1.40–83.97)
8.19±6.83  
(1.40–53.21)
12.67±11.24 
(1.96–83.97)
Morbidities
 Diabetes mellitus 128 (30.3) 64 (28.3) 64 (32.5)
 Arterial hypertension 338 (79.9) 176 (77.8) 162 (82.2)
 Renal impairment 59 (13.9) 31 (13.7) 28 (14.2)
  Peripheral artery  
disease
43 (10.2) 23 (10.2) 20 (10.1)
 Carotid stenosis 41 (9.7) 17 (7.5) 24 (12.2)
 COPD 72 (17.0) 37 (16.3) 35 (17.7)
  History of cerebral  
events
31 (7.3) 17 (7.5) 14 (7.1)
Concomitant proceduresa
 CABG – 34 (17.3)
 Grafts, n – 1.9±1.0
 CABG + MvR – 7 (3.5)
 CABG + TvR – 2 (1.0)
 MvR (DvR) – 18 (9.3)
 MvR (DvR) + TvR – 6 (3.9)
 TvR – 4 (2.0)
 Ascendens tube graft – 6 (3.0)
 Ablation – 16 (8.1)
 PFO-closure – 11 (5.6)
 Other – 5 (2.5)
Labeled valve size
 #19 10 (2.4) 6 (2.6) 4 (2.0)
 #21 109 (25.8) 62 (27.4) 47 (23.8)
 #23 133 (31.4) 69 (30.5) 64 (32.5)
 #25 124 (29.3) 66 (29.2) 58 (29.5)
 #27 47 (11.1) 23 (10.2) 24 (12.2)
Notes: aOne or more combined procedures. Unspecified data are n (%) 
and mean ± SD.
Abbreviations: AvR, aortic valve replacement; BMi, body mass index; BSA, body 
sur face area; CABG, coronary artery bypass grafting; COPD, chronic obstructive 
pulmonary disease; DvR, double valve replacement; LveF, left ventricular ejection 
fraction; MvR, mitral valve repair/replacement; PFO, patent foramen ovale; SD, standard 
deviation; STS, Society of Thoracic Surgeons; TvR, tricuspid valve repair (annuloplasty).
be considered unsuitable because of the missing commis-
sure landmark and coexisting aortic wall pathology, which 
may cause subsequent sinotubular junction dilatation and 
potentially lead to regurgitation. Although the FS valve 
provides some tolerance to mismatch between the annulus and 
sinotubular junction because of a large coaptation surface,22 
implantation of the FS should be restricted in enlarged aortas. 
Massive calcification of the aortic sinus wall and root are 
also incompatible with FS use as in this case, supra-annular 
suturing becomes impossible.19
Results and experiences
Operating time and learning curve
The first author has collected the FS experience at two 
institutions (University Hospital, [Berne, Switzerland] and 
University Hospital Salzburg [Salzburg, Austria]); therefore 
the combined numbers are reported here. Data on patient 
characteristics, procedures, outcome, and complications are 
presented in Tables 1 and 2. In total, 423 AVR procedures 
with the FS were performed by ten different surgeons, six of 
whom completed .20 procedures (range: 23–152). The mean 
extracorporeal circulation (ECC) and cross-clamp times were, 
respectively, 89±29 minutes (64±21 minutes) for isolated 
procedures and 123±43 (87±29 minutes) for combined pro-
cedures, with no significant differences among valve sizes 21, 
23, 25, and 27. The indications were aortic stenosis (80.2%), 
regurgitation (4.0%), and combined pathologies (15.8%). 
Fourteen patients were operated for active endocarditis.
The median ECC and cross-clamp times decreased, on 
average, by 10% after the first ten isolated AVR procedures 
for each surgeon and a further 5% after the next ten implants, 
suggesting a short learning curve with the new technique. 
However, individual data varied and was likely biased by 
proctoring and teaching engagements by all of the surgeons, 
thus overestimating the required operating times.
For comparison, the mean ECC and cross-clamp times 
for the PF stentless valve that requires two suture lines were 
136±65 minutes (105±51 minutes) for isolated procedures 
and 147±28 (115±24 minutes) for combined procedures, 
respectively. Therefore, for isolated and combined procedures, 
respectively, operating times for the FS are 20% and 36.5% 
shorter as a result of the ability to avoid one suture line.
Operative mortality and early 
complications
The logistic EuroScore for isolated and combined procedures 
were 8.2±6.8 and 12.7±11.2 (12.8±13.3), respectively. The 
overall 30-day mortality in our cohort was 3.8% (1.8% for iso-
lated AVR and 6.1% for combined procedures) (Table 2). This 
data is comparable with 2.3%–4.9% mortality obtained with 
variable percentages of combined procedures (16%–60%) 
reported elsewhere (Table 3).32–36 Causes of early death were 
low cardiac output/myocardial infarction, multiorgan failure, 
cerebral embolism, and septic endocarditis. None of the 
deaths was valve-related. Nonsurviving patients were sig-
nificantly older (78.3±5.0 years vs 73.9±7.3 years) (P,0.05) 
and had a higher logistic EuroScore (17.4±22.1 vs 9.3±7.4) 
(P=0.252) as compared with the surviving patients.
Research Reports in Clinical Cardiology 2014:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
354
Stanger et al
Table 2 Outcome and complication in 423 consecutive patients 
receiving Freedom SOLO
Total AVR 
isolated
AVR 
combined
n 423 226 197
eCC time, all (min) 104±40 89±29 123±43
Cross-clamp time, all (min) 75±28 64±21 87±29
RBC, units 2.9±1.8a 2.5±1.5c 3.3±2.1d
Platelets, units 1.8±1.1b 1.7±1.0e 1.9±1.1f
30-day mortality 16 (3.8) 4 (1.8) 12 (6.1)
Cause of death
 LCO 9 2 7
 Sepsis 3 1 2
 MOF 2 – 2
 Bleeding 1 1 –
 Neurology 1 – 1
30-day complications
 Rethoracotomy for bleeding 11 (2.6) 4 (1.7) 7 (5.5)
 Reversible cerebral eventg 13 (3.1) 4 (1.7) 9 (4.5)
 AKF, hemofiltration 14 (3.3) 4 (1.8) 10 (5.1)
 wound infection 11 (2.6) 2 (0.9) 9 (4.5)
Permanent pacemaker 8 (1.9) 3 (1.3) 5 (2.5)
 Previously SR 5 (1.2) 2 (0.9) 3 (1.5)
 Previously AFib, heart block 3 (0.7) 1 (0.4) 2 (0.7)
5-year complications
 endocarditis 1 (0.2) 1 (0.4) –
 Prosthesis explantation 4 (0.9) 1 (0.4) 3 (1.5)
 Severe regurgitation 3 (0.7) – 3 (1.5)
 Severe stenosis 1 (0.2) 1 (0.4) –
 SvD – – –
 Thromboembolism – – –
PPM, moderateh 17 (4.0) 14 (4.9) 3 (1.5)
PPM, severe – – –
Notes: a55.2% of patients received RBC units; b12.7% of patients received platelet 
units; c52.8%; d57.9%; e9.7%; f16.5%; g6 patients with previous stroke; hpatients’ BMi: 
34.7±3.8 (28.3–40.6). Unspecified data are n (%) and mean ± SD.
Abbreviations: AFib, atrial fibrillation; AKF, acute kidney failure; AVR, aortic valve 
replacement; BMi, body mass index; eCC, extracorporeal circulation; LCO, low 
cardiac output; MOF, multiorgan failure; PPM, prosthesis–patient mismatch; RBC, 
red blood cells; SD, standard deviation; SR, sinus rhythm; SvD, structural valve 
deterioration.
All patients left the operating room with no or trivial 
regurgitation. There were no other intraoperative events 
or technical complications with FS valve prosthesis 
 implantations. The low rates of postoperative cerebral events 
(3.1%), impaired renal function requiring temporary hemofil-
tration (3.3%), or wound healing complications (2.6%) were 
not different to AVR with stented prostheses (Table 2). All 
patients were discharged without further complications. The 
hospital lengths of stay for isolated and combined AVR were 
9.6±1.9 days and 11.0±2.8 days, respectively.
Requirement for permanent pacemaker
Postoperative complete atrioventricular (AV) block and 
severe symptomatic bradycardia, as typical post-AVR com-
plications, are rare in patients receiving the FS. Low rates, 
of 0%–3.0%, of permanent pacemaker (PM) implantation 
have been reported for patients receiving the FS.32,33,37,38 
This data is in line with the requirement for permanent PM 
implantation after isolated AVR with stented prostheses in 
7.0% of patients, in a recent meta-analysis including 2,557 
patients for best evidence analyses.39 The low rate of per-
manent PM (Table 2) in patients receiving the FS could be 
explained by the implantation technique, which strictly fol-
lows supra-annular positioning and therefore avoids trauma to 
the AV node or His bundle in the region of the membranous 
septum and right trigonum, beneath the NC to right coronary 
cusp commissure. Rare cases of damage to the conduction 
system could be explained by aggressive (excessive) decal-
cification in the area of the septum membranaceum just prior 
to prosthesis implantation.
Hemodynamic performance: gradients  
at rest and under stress
Clinical studies have shown that stentless valves in the sub-
coronary position provide residual transvalvular gradients 
similar to native valves and unmatched by traditional stented 
prostheses at early to midterm follow up.40 The hemodynamic 
data in our cohort are shown in Figure 3 and in Table 4 for 
individual valve sizes. Postoperative gradient reduction 
remained stable within valve size groups, with a slight trend 
toward lower mean gradients with increasing valve size. 
These low gradients may be of particular benefit for patients 
with preoperatively (impaired) poor LV function.
Most studies reported transvalvular gradients at rest, 
although gradients during stress (exercise) testing would 
better reflect prosthesis-related limitations. With increas-
ing cardiac output, the transvalvular flow also increases 
and the rise in transprosthetic gradient is an important 
index for adequate valvular function. In general, at mid-
term follow up, gradients at rest and during exercise, as 
well as the rise, were found to be lower in patients with 
stentless prostheses compared with stented valves, indi-
cating that the stentless valve may perform better under 
physiological stress.41,42
In patients after AVR with FS, resting and stress gradi-
ents have been investigated using the bicycle exercise test at 
9.6 months postsurgery.36 During stress echocardiography, 
mean aortic gradients increased only from 4.4±1.7 mmHg at 
rest to 7.0±2.7 mmHg at peak stress, and the EOA increased 
from 1.74±0.33 cm2 to 1.80±0.36 cm2. Mean gradients at peak 
stress correlated better with resting indexed EOA than with 
the labeled prosthesis size.36 These data are in line with the 
ideal adaption of the FS prosthesis to the patient’s anatomy, 
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Table 3 Thirty-day mortality and long-term complications
N Mean follow-up  
(years)
30-day  
mortality
At  
4 years
At  
8 years
Reference
30-day mortality 423 5.5±2.3 3.8 This study
100 1.0±0.4 3.0 Oses et al32
77 3.1±0.1 4.6 iliopoulos33
256 1.1±0.8 2.3 Beholz et al34
143 1.8±1.4 4.9 Horst et al35,a
277 2.6±1.7 4.3 Thalmann et al37
Freedom from endocarditis 149 5.5±2.3 0.98 0.96 This study
256 1.1±0.8 97.4 Beholz et al34
143 1.8±1.4 99.3 Horst et al35,a
Freedom from SvD 149 5.5±2.3 0.97 0.70 This study
256 1.1±0.8 1.00 Beholz et al34
143 1.8±1.4 100 Horst et al35,a
Freedom from explantation 149 5.5±2.3 0.96 0.81 This study
256 1.1±0.8 97.8 Beholz et al34
143 1.8±1.4 98.6 Horst et al35,a
Freedom from explantation for SvD 149 5.5±2.3 1.00 0.84 This study
Freedom from thromboembolism 149 5.5±2.3 0.99 0.99 This study
256 1.1±0.8 98.8 Beholz et al34
143 1.8±1.4 1.00 Horst et al35,a
Note: aData was observed at 4.7 years.
Abbreviation: SvD, structural valve deterioration.
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Figure 3 Gradients (peak and mean) after implantation of the Freedom SOLO valve.
Abbreviations: Preop, preoperative; Postop, postoperative.
following the natural motion of the annulus. Therefore, 
stentless valves could be preferable for more active patients, 
particularly those with a small aortic root.
Lv mass regression
The LV mass regression (LVMR) is related to the EOA 
and the following decline in transaortic pressure differ-
ence.43  Postoperative regression of LVH, eg, decreases of 
LV end-diastolic diameter, LV end-systolic diameter, and 
interventricular septum thickness, following AVR with FS 
have been reported after 1 year.33,37 Compared with stented 
bioprostheses or mechanical valves, a more rapid and more 
complete resolution of LVH in relation to remodeling 
and improved function have been reported.44,45 In general, 
 differences in LVMR between stented and stentless valves 
persisted until 1 year postsurgery, but not longer.43–47 There-
fore, these results indicate that LVMR may occur faster in 
stentless valves during the first year postsurgery.47
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shown to have noninferior EOA compared with the FS, with 
favorable hemodynamic performance and with low rates of 
PPM due to improved design.50 As such, the EOA for the vari-
ous valve sizes 19–27 ranged from 1.53–3.20 cm2, with mean 
gradients of 4.7–11.4 mmHg, for the Trifecta bioprosthesis 
at 1 year.50,51 The corresponding EOA and gradients for the 
Perimount Magna Ease valves ranged from 2.09–2.80 cm2 and 
11.3–14.1 mmHg,50 with near absence (#1%) of PPM.52,53
Coronary flow and coronary flow 
reserve
Coronary flow (CF) (perfusion) and coronary flow reserve 
(CFR) patterns are impaired in patients with aortic steno-
sis. In fact, valve-related chronic coronary hypoperfusion 
and reduced CFR may cause angina pectoris, arrhythmia, 
deteriorating LV function,54 and sudden cardiac death, and 
were shown to be independent predictors of cardiovascular 
prognosis.55
Given that CF is determined by the diastolic flow pattern 
within the sinus of Valsalva, restoration of postoperative CFR 
depends on the turbulence downstream of the valve, which 
in turn, is fundamentally dependent on prosthesis design 
and orientation.54,55 Optimal valve orientation with respect to 
hemodynamics results in CF rates closest to normal physiol-
ogy. The correlation between systolic performance and CF 
is explained by low levels of turbulence downstream during 
systole, which also affects diastolic backflow. Thus, the 
optimally oriented valve allows normal diastolic regurgita-
tion into the sinuses of Valsalva and provides the highest CF 
rates.54 As demonstrated with magnetic resonance imaging 
(MRI), postoperative increases in CF and CFR were signifi-
cantly higher in patients receiving stentless valves (Medtronic 
Freestyle®) than stented prostheses (Medtronic Mosaic®).56 
Furthermore, normalization of CFR after AVR in patients 
with aortic stenosis (AS) was observed only for stentless 
valves and not with stented bioprostheses (Medtronic Mosaic) 
or with mechanical valves (Medtronic Hall; Medtronic 
Advantage®).57 Importantly, no correlation between valve size 
and CF rates was observed.54 In conclusion, compared with 
stented bioprostheses or mechanical valves, use of stentless 
valves provides superior hemodynamic performance, includ-
ing increased CF and restoration of a normal CFR.
Transient postoperative 
thrombocytopenia
In agreement with previous reports,27,32–34,58–60 we observed a 
more severe postoperative platelet decrease following implan-
tation of the FS when compared with stented bioprostheses. 
Table 4 Gradients according to prosthesis size after AvR with 
Freedom SOLO
N Gradients
Preoperative 30 days 6 months 1 year
#19 10
 Peak 73.2±30.3 19.5±7.0 17.4±7.0 16.9±8.1
 Mean 50.1±21.0 10.5±4.8 11.0±4.9 10.6±4.1
#21 109
 Peak 83.8±20.6 18.3±6.4 18.8±6.6 18.0±8.7
 Mean 55.0±14.6 9.9±3.8 10.4±5.1 9.9±3.9
#23 133
 Peak 75.7±22.4 17.5±6.4 16.1±6.2 16.0±7.8
 Mean 47.6±15.0 9.9±3.5 9.2±3.5 9.6±4.6
#25 124
 Peak 77.8±19.8 14.6±5.5 13.6±4.7 13.8±4.3
 Mean 48.6±14.4 8.3±3.2 7.9±2.8 7.9±2.2
#27 47
 Peak 66.3±26.9 14.5±5.9 14.8±6.4 13.8±7.4
 Mean 43.6±16.0 8.0±3.1 8.5±3.4 7.4±2.8
Total 423
 Peak 77.4±22.1 15.9±5.8 15.7±6.7 16.2±7.7
 Mean 49.1±15.0 9.1±3.5 8.8±3.2 9.3±4.3
Note: Data are presented as mean ± standard deviation.
Abbreviation: AvR, aortic valve replacement.
eOA and prosthesis–patient mismatch
Prosthesis–patient mismatch (PPM) has been associated with 
higher gradients (at rest and particularly under stress condi-
tions), blunted LVMR,48 and increased all-cause and cardiac-
related mortality over long-term follow up, particularly in 
younger patients, females, and patients with preoperative LV 
dysfunction.49 As generally accepted, PPM is best characterized 
by the ratio of prosthetic EOA to the patient’s body surface area 
(BSA). PPM is defined as an indexed EOA between 0.85–0.65 
cm2/m2 (moderate) and ,0.65 cm2/m2 (severe), which is the 
common cutoff value for all kinds of prosthetic valves.48 
Depending on prosthesis size, the EOA increases two- to three-
fold after FS implantation and was reported (mean ± standard 
deviation [SD]) for the valve sizes 19, 21, 23, 25, and 27, as 
1.49±0.32 cm2, 1.67±0.40 cm2, 1.92±0.38 cm2, 2.01±0.42 cm2, 
and 2.13±0.36 cm2, respectively.37 Calculations for the indexed 
EOA (EOA/BSA) indicated complete absence of severe PPM 
with the FS valve prosthesis, and only moderate PPM in 17 
patients (4.0%) with a BSA of 2.09±0.2 m2 (body mass index 
[BMI] 34.5±3.9 kg/m2). Due to the favorable EOA with absence 
of obstructive stents, this valve appears particularly attractive for 
patients at risk for PPM, ie, those with a small aortic root.
However, new-generation stented valves, eg, the 
 Carpentier-Edwards Perimount Magna Ease (Edwards Life-
sciences, Irvine, CA, USA), Mitroflow (Sorin Biomedica) and 
the Trifecta™ (St Jude Medical, St Paul, MN, USA), were 
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The minimal platelet count was observed on the second 
postoperative day (mean -62%). Importantly, we and others 
have not observed associated excess bleeding complications 
or increased reexploration rates despite this transient 
thrombocytopenia. In comparison, platelet numbers recovered 
to baseline values (100%) on postoperative day 6 and 9, for the 
Mitroflow and FS, respectively (Figure 4). The initial discovery 
of this FS-associated phenomenon came about with the inves-
tigation into the cause of unexpected increases in requested 
heparin-induced thrombocytopenia (HIT) tests following AVR 
in patients receiving this prosthesis.27,59 However, no evidence 
suggests any link to HIT.61 Platelet activation and aggregation 
result in diffuse platelet consumption and decreased platelet 
count, but to date, no FS-associated thromboembolic compli-
cations have been reported. Furthermore, no impairment in 
platelet–fibrinogen interactions for thrombus formation and no 
change in postoperative platelet function have been observed.62 
Causal hemodynamic stress appears highly unlikely given the 
large EOA and low gradients of a correctly sized FS,37 with 
performances similar to native aortic valves under rest and 
stress conditions.63
At this point, the precise mechanism of FS-dependent 
thrombocytopenia remains to be identified. As mentioned, the 
FS bioprosthesis undergoes antimineralization treatment with 
HCA, a reactive intracellular oxidation product of the sulfur-
containing amino acid homocysteine, which is usually not 
measurable in peripheral blood. An alternative hypothesis to 
explain FS-associated postoperative thrombocytopenia could 
be the platelet lysis induced through HCA-dependent hyper-
activation of membrane N-methyl-D-aspartic acid (NMDA)-
type glutamate receptors on activated platelets. This receptor 
activation can be followed by increases in intracellular 
levels of ionized calcium, cyclic adenosine monophosphate 
(cAMP) levels, and reactive oxygen species (ROS), which 
trigger expression of proapoptotic genes, progressive cellular 
degeneration, and cell lysis within hours of even short-term 
HCA exposures.64,65 This mechanism may be limited to the 
subgroup of platelets that are particularly susceptible to 
damage and stimulation after ECC. Furthermore, the short, 
nonpersistent damaging effect would also be limited to the 
short time when the FS surface is fully exposed following 
implantation, explaining the transient decrease of platelet 
numbers with recovery.
Long-term outcome and 
reoperation
Numerous reports have documented superior early and mid-
term hemodynamic results following stentless valve prostheses 
implantation, including the FS.47,66 However, stentless valves 
must demonstrate at least noninferiority to stented biopros-
theses in long-term outcomes studies to obtain full acceptance. 
The FS was introduced in 2004, and we are thus now approach-
ing a critical observation period, which will enable evaluation 
of the long-term durability of the FS prosthesis and the validity 
of the concept of current third-generation stentless valves. Not 
much data on the FS with longer observation periods has been 
published (Table 3). Rates for freedom from endocarditis, SVD, 
explantation, and explantation for SVD after 8 years in a cohort 
of 149 patients were 0.96 (0.90–0.99), 0.70 (0.57–0.80), 0.81 
(0.67–0.89), and 0.84 (0.70-0.92), respectively (Figure 5). In all 
cases of nonsclerotic SVD, acute vertical tears of the noncoror-
nary cusp were located in close proximity to the commissure, 
and in our series, they occurred, on average, 1.5 years (6.0 vs 
7.5 years) earlier than explantation for degenerative stenosis. 
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Calcification was always strikingly severe and included the 
entire aortic root.
FS prostheses with tears and cusp ruptures were relatively 
easy to replace. In contrast, the majority of cases with severe 
calcification turned out to be very difficult to decalcify. FS 
valves were replaced with prostheses at least one size smaller 
than the original FS size. In some extremely demanding 
cases, a complete root replacement may be necessary. Our 
experience confirms the findings of a previous report that 
reoperations after stentless AVR are challenging and more 
complex procedures than a simple “redo” of AVR and are 
associated with increased operative risks.67 Alternatively, 
successful treatment of stenotic FS with transcatheter aortic 
valve implantation (TAVI) has been reported and may become 
increasingly important.68
Conclusion
Stentless valves were developed to mimic as much as possible 
the anatomy and physiology of the native aortic valve and to 
simplify and standardize the method of implantation.
The third-generation FS valve is a very attractive alter-
native to stented bioprostheses. The design, and tissue and 
anticalcification treatment fulfill most, if not all, requirements 
of an ideal valve substitute. The FS pericardium stentless 
valve combines the single-suture, subcoronary implantation 
technique with the latest-generation bovine pericardial tissue 
and novel anticalcification treatment. The design allows a 
good imitation of the native healthy aortic valve through 
unrestricted adaption to the patient’s anatomy, reproducing 
a normal valve/root complex. Further advantages of the FS 
include the absence of subclinical hemolysis,69 the absence 
of imaging artifacts (on computed tomography [CT]/MRI), 
and potential strut-related obstruction of coronary ostia.
Thus, in theory, stentless valve function and durability 
have been expected to be superior to those of stented valves. 
However, despite the fact that the majority of patients under-
going AVR with bioprostheses have a remaining lifetime 
of less than 10 to 12 years, major concerns for stentless 
prostheses relate to issues regarding long-term durability. 
Whereas many investigators report consistently on short-term 
outcome with excellent early hemodynamic performance, 
long-term durability of these valves is rarely reported and 
remains largely uncharacterized. Furthermore, there are 
concerns of early structural and nonstructural deterioration. 
In fact, no stentless valve has proven superiority for long-
term durability.
A number of stentless models have been developed and 
introduced, but all have been fundamentally different with 
respect to design, and tissue and anticalcification treatment, 
rendering comparisons difficult. One point of criticism has 
been the variety of implantation techniques (subcoronary, 
“miniroot”, and full-root replacement), all of which are 
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considered more complex procedures requiring two or more 
suture lines and consequently, accounting for a longer operat-
ing time as compared with stented valves.
Freedom from thromboembolism and endocarditis follow-
ing bioprosthetic valve replacement is usually very good, with 
values typically greater than 90% at 7 to 10 years.70 However, 
after approximately 10 years, freedom from SVD and reopera-
tion dropped dramatically in earlier porcine models, eg, the 
O’Brien (CryoLife, Atlanta, GA, USA),71 Shelhigh (Shelhigh, 
Inc., Millburn, NJ, USA),72 and Biocor™ (St Jude Medical).73 
Furthermore, the freedom from SVD and explantation for 
SVD in our cohort was 0.84 (0.70–0.92) and 0.76 (0.50–0.89), 
respectively, after 8 and 9 years, which is comparable with 
similar data reported for the subcoronary Toronto stentless 
valve. These results imply then that the durability is lower 
than that of traditional stented prostheses.70
If, despite all the beneficial aspects mentioned above, 
durability is inferior to stented valves, must we question 
manufacturing details or the whole stentless concept? It 
is difficult to see where the design can undergo further 
improvement. Reoperation includes valve-dependent but 
also valve-independent failure. Therefore we have learned 
that outcomes also depend on optimal patient selection and 
observance of the limitations for the use of stentless valves, 
particularly with the FS.
Importantly, the stentless valve prosthesis concept ideally 
assumes that it can replace and imitate a native valve, thus 
adopting nearly identical functional durability. However, this 
theoretical idea ignores that the stentless valve may not seat 
adequately in the native aortic root. Optimal performance and 
long-term freedom from SVD depends on perfectly symmet-
ric implantation, to provide low leaflet stress. In reality, this is 
only rarely obtained since the distribution of the three sinuses 
is never really symmetrical. As a fundamental difference, the 
function of stented valves is fully separated from the sinus 
function, whereas stentless valves are fully exposed to the 
interaction between aortic root dynamics and valve mechan-
ics. Any malpositioning can thus lead to tissue fatigue over 
time. Given the large individual variability in root anatomy, 
particularly of the NC sinus, which is usually larger than the 
left coronary and right coronary sinuses (with corresponding 
larger volume, increased height, width, leaflet size, and thick-
ness),74 symmetric implantation and tension-free positioning 
can hardly be guaranteed. Therefore, any asymmetry between 
the native anatomy and the stentless tissue valve may cause 
small distortions, with eccentric regurgitation, increased 
chronic mechanical stress, and premature valve deterioration. 
Whereas a compliant aortic root contributes substantially 
to smooth and symmetrical leaflet opening with minimal 
gradients, this effect is strikingly absent with stiff roots and 
may also contribute to premature SVD.75 At least, the annulus 
must be considered stiff and noncompliant in patients with 
sclerotic aortic stenosis, arguing for impaired root physiology 
with implication for prosthesis durability.
In this review, we have described the implantation tech-
nique for the FS, including pitfalls in detail, and have given 
an overview of our own clinical experience. Beyond doubt 
and in contrast to stented valves, despite the single suture 
line and reproducible outcomes through more standardized 
techniques, stentless valve implantation still requires more 
demanding techniques, more experienced surgeons, and 
 surgeon-dependent skills, which include good judgment, 
proper patient selection, and respect for limitations. We are 
now approaching a period of observation, which will be criti-
cal in defining the concept of current third-generation stentless 
valves. Regardless of whether or not stentless valve durability 
surpasses third-generation stented bioprostheses, stentless 
valves will continue to play a role in the surgical repertoire.
Acknowledgment
We are grateful to Sarah Longnus and Brigitta Gahl for 
excellent technical assistance in preparing and reviewing 
the manuscript.
Disclosure
The authors report no conflict of interest in this work.
References
 1. Hufnagel CA, Harvey WP, Rabil PJ, McDermott TF. Surgical correction 
of aortic insufficiency. Surgery. 1954;35(5):673–683.
 2. Ross DN. Homograft replacement of the aortic valve. Lancet. 1962; 
2(7254):487–488.
 3. Barratt-Boyes BG. Homograft aortic valve replacement in aortic 
incompetence and stenosis. Thorax. 1964;19(2):131–150.
 4. Harken DE, Soroff HS, Taylor WJ, Lefemine AA, Gupta SK, Lunzer S. 
Partial and complete prostheses in aortic insufficiency. J Thorac 
 Cardiovasc Surg. 1960;40:744–762.
 5. Weldon CS, Ameli MM, Morovati SS, Shaker IJ. A prosthetic 
stented aortic homograft for mitral valve replacement. J Surg Res. 
1966;6(12):548–552.
 6. Duran CG, Gunning AJ. Heterologous aortic valve transplantation in 
the dog. Lancet. 1965;1(7403):114–115.
 7. Binet JP, Carpentier A, Langlois J, Duran C, Colvez P. [Implantation of 
heterogenic valves in the treatment of aortic cardiopathies]. C R Acad 
Sci Hebd Seances Acad Sci D. 1965;261(25):5733–5734. French.
 8. Binet JP, Duran CG, Carpentier A, Langlois J. Heterologous aortic 
valve transplantation. Lancet. 1965;286(7425):1275.
 9. Carpentier A, Deloche A, Relland J, et al. Six-year follow-up of 
glutaraldehyde-preserved heterografts. With particular reference to 
the treatment of congenital valve malformations. J Thorac Cardiovasc 
Surg. 1974;68(5):771–782.
 10. Reis RL, Hancock WD, Yarbrough JW, Glancy DL, Morrow AG. The 
flexible stent. A new concept in the fabrication of tissue heart valve 
prostheses. J Thorac Cardiovasc Surg. 1971;62(5):683–689.
Research Reports in Clinical Cardiology 2014:5submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
360
Stanger et al
 11. Bortolotti U, Milano A, Thiene G, et al. Early mechanical failures 
of the Hancock pericardial xenograft. J Thorac Cardiovasc Surg. 
1987;94(2):200–207.
 12. Harken DE. Heart valves: ten commandments and still counting. Ann 
Thorac Surg. 1989;48(Suppl 3):S18–S19.
 13. Walkes JC, Reardon MJ. Current thinking in stentless valve surgery. 
Curr Opin Cardiol. 2003;18(2):117–123.
 14. O’Brien MF. The Cryolife-O’Brien composite aortic stentless 
 xenograft: surgical technique of implantation. Ann Thorac Surg. 1995; 
60(Suppl 2):S410–S413.
 15. Dagum P, Green GR, Nistal FJ, et al. Deformational dynamics of 
the aortic root: modes and physiologic determinants. Circulation. 
1999;100(Suppl 19):II54–II62.
 16. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP.  Prognostic 
implications of echocardiographically determined left ventricular 
mass in the Framingham Heart Study. N Engl J Med. 1990;322(22): 
1561–1566.
 17. Lund O. Valve replacement for aortic stenosis: the curative poten-
tial of early operation. Scand J Thorac Cardiovasc Surg Suppl. 
1993;40:S1–S137.
 18. Stacchino C, Bona G, Rinaldi S, Vallana F. Design and performance 
characteristics of the Pericarbon Stentless valve. J Heart Valve Dis. 
1995;4 Suppl 1:S102–S105.
 19. Stacchino C, Bona G, Bonetti F, et al A. Grignani. Detoxification 
process for glutaraldehyde-treated bovine pericardium:  biological, 
chemical and mechanical characterization. J Heart Valve Dis. 
1998;7(2),190–194.
 20. Repossini A, Kotelnikov I, Bouchikhi R, et al. Single-suture line 
placement of a pericardial stentless valve. J Thorac Cardiovasc Surg. 
2005;130(5):1265–1269.
 21. O’Brien MF. Implantation technique of the Cryolife-O’Brien stentless 
xenograft aortic valve: the simple, rapid, and correct way to implant and 
the errors to avoid. Semin Thorac Cardiovasc Surg. 1999;11(4 Suppl 1): 
S121–S125.
 22. Scharfschwerdt M, Sievers HH, Hussein A, Kraatz EG, Misfeld M. 
Impact of progressive sinotubular junction dilatation on valve com-
petence of the 3F Aortic and Sorin Solo stentless bioprosthetic heart 
valves. Eur J Cardiothorac Surg. 2010;37(3):631–634.
 23. David TE, Feindel CM, Bos J, Ivanov J, Armstrong S. Aortic valve 
replacement with Toronto SPV bioprosthesis: optimal patient sur-
vival but suboptimal valve durability. J Thorac Cardiovasc Surg. 
2008;135(1):19–24.
 24. Glauber M, Solinas M, Karimov J. Technique for implant of the stentless 
aortic valve Freedom Solo. Multimed Man  Cardiothorac Surg [serial on the 
Internet]. Jan 2007 [cited September 21, 2014]; 2007(1018):[about 10 p]. 
http://mmcts.oxfordjournals.org/content/2007/1018/mmcts.2007.002618.
full.pdf+html. Accessed September 21, 2014.
 25. Permanyer E, Ginel A, Muñoz-Guijosa C, Padró JM. The Sorin 
Freedom SOLO stentless aortic valve: easier implantation technique 
with potentially less risk of complications. Eur J Cardiothorac Surg. 
2011;40(5):1263–1264.
 26. Beholz S, Konertz WE. Avoiding early partial valve thrombosis of 
the Pericarbon Freedom stentless valve. J Heart Valve Dis. 2007; 
16(1):91–92.
 27. Hilker L, Wodny M, Ginesta M, Wollert HG, Eckel L. Differences in 
the recovery of platelet counts after biological aortic valve replacement. 
Interact Cardiovasc Thorac Surg. 2009;8(1):70–73.
 28. Sinha P, Zurakowski D, Kumar TK, He D, Rossi C, Jonas RA. Effects 
of glutaraldehyde concentration, pretreatment time, and type of tissue 
(porcine versus bovine) on postimplantation calcification. J Thorac 
Cardiovasc Surg. 2012;143(1):224–227.
 29. Valente M, Pettenazzo E, Thiene G, et al. Detoxified glutaraldehyde cross-
linked pericardium: tissue preservation and mineralization mitigation in 
a subcutaneous rat model. J Heart Valve Dis. 1998;7(3):283–291.
 30. Ozaki S, Herijgers P, Flameng W. Influence of blood contact on the 
calcification of glutaraldehyde-pretreated porcine aortic valves. Ann 
Thorac Cardiovasc Surg. 2003;9(4):245–252.
 31. Perrotta S, Lentini S. In patients with severe active aortic valve 
endocarditis, is a stentless valve as good as the homograft? Interact 
Cardiovasc Thorac Surg. 2010;11(3):309–313.
 32. Oses P, Guibaud JP, Elia N, et al. Freedom SOLO valve: early- and 
intermediate-term results of a single centre’s first 100 cases. Eur J 
Cardiothorac Surg. 2011;39(2):256–261.
 33. Iliopoulos DC, Deveja AR, Androutsopoulou V, et al. Single-center 
experience using the Freedom SOLO aortic bioprosthesis. J Thorac 
Cardiovasc Surg. 2013;146(1):96–102.
 34. Beholz S, Repossini A, Livi U, et al. The Freedom SOLO valve for 
aortic valve replacement: clinical and hemodynamic results from a 
prospective multicenter trial. J Heart Valve Dis. 2010;19(1):115–123.
 35. Horst M, Easo J, Hölzl PP, et al. The Freedom SOLO valve:  mid-term 
clinical results with a stentless pericardial valve for aortic valve 
 replacement. J Heart Valve Dis. 2011;20(6):704–710.
 36. Repossini A, Rambaldini M, Lucchetti V, et al. Early clinical and 
haemodynamic results after aortic valve replacement with the Freedom 
SOLO bioprosthesis (experience of Italian multicenter study). Eur J 
Cardiothorac Surg. 2012;41(5):1104–1110.
 37. Thalmann M, Kaiblinger J, Krausler R, et al. Clinical experience with 
the Freedom SOLO stentless aortic valve in 277 consecutive patients. 
Ann Thorac Surg. Epub August 20, 2014.
 38. Aymard T, Eckstein F, Englberger L, Stalder M, Kadner A, Carrel T. 
The Sorin Freedom SOLO stentless aortic valve: technique of implanta-
tion and operative results in 109 patients. J Thorac Cardiovasc Surg. 
2010;139(3):775–777.
 39. Matthews IG, Fazal IA, Bates MG, Turley AJ. In patients undergoing 
aortic valve replacement, what factors predict the requirement for 
permanent pacemaker implantation? Interact Cardiovasc Thorac Surg. 
2011;12(3):475–479.
 40. Dellgren G, Feindel CM, Bos J, Ivanov J, David TE. Aortic valve 
replacement with the Toronto SPV: long-term clinical and  hemodynamic 
results. Eur J Cardiothorac Surg. 2002;21(4):698–702.
 41. Kunadian B, Vijayalakshmi K, Thornley AR, et al. Meta-analysis of 
valve hemodynamics and left ventricular mass regression for stentless 
versus stented aortic valves. Ann Thorac Surg. 2007;84(1):73–78.
 42. Silberman S, Shaheen J, Fink D, et al. Comparison of exercise hemo-
dynamics among nonstented aortic bioprostheses, mechanical valves, 
and normal native aortic valves. J Card Surg. 1998;13(5):412–416.
 43. Del Rizzo DF, Abdoh A, Cartier P, Doty D, Westaby S. Factors 
affecting left ventricular mass regression after aortic valve replace-
ment with stentless valves. Semin Thorac Cardiovasc Surg. 1999; 
11(4 Suppl 1):114–120.
 44. Maselli D, Pizio R, Bruno LP, Di Bella I, De Gasperis C. Left ventricular 
mass reduction after aortic valve replacement: homografts, stentless and 
stented valves. Ann Thorac Surg. 1999;67(4):966–971.
 45. Walther T, Falk V, Langebartels G, et al. Regression of left ventricular 
hypertrophy after stentless versus conventional aortic valve  replacement. 
Semin Thorac Cardiovasc Surg. 1999;11(4 Suppl 1):S18–S21.
 46. Cohen G, Zagorski B, Christakis GT, et al. Are stentless valves 
hemodynamically superior to stented valves? Long-term follow-up of 
a randomized trial comparing Carpentier-Edwards pericardial valve 
with the Toronto Stentless Porcine Valve. J Thorac Cardiovasc Surg. 
2010;139(4):848–859.
 47. Funder JA. Current status on stentless aortic bioprosthesis: 
a clinical and experimental perspective. Eur J Cardiothorac Surg. 
2012;41(4):790–799.
 48. Pibarot P, Dumesnil JG. Prosthesis-patient mismatch: definition, clinical 
impact, and prevention. Heart. 2006;92(8):1022–1029.
 49. Head SJ, Mokhles MM, Osnabrugge RL, et al. The impact of prosthesis-
patient mismatch on long-term survival after aortic valve replacement: 
a systematic review and meta-analysis of 34 observational studies 
comprising 27 186 patients with 133 141 patient-years. Eur Heart J. 
2012;33(12):1518–1529.
 50. Ugur M, Suri RM, Daly RC, et al. Comparison of early hemodynamic 
performance of 3 aortic valve bioprostheses. J Thorac Cardiovasc Surg. 
Epub January 15, 2014.
Research Reports in Clinical Cardiology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/research-reports-in-clinical-cardiology-journal
Research Reports in Clinical Cardiology is an international, peer-
reviewed, open access journal publishing original research, reports, 
editorials, reviews and commentaries on all areas of cardiology in the 
clinic and laboratory. The manuscript management system is com-
pletely online and includes a very quick and fair peer-review system. 
Visit http://www.dovepress.com/testimonials.php to read real quotes 
from published authors.
Research Reports in Clinical Cardiology 2014:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
361
SOLO stentless valve
 51. Bavaria JE, Desai ND, Cheung A, et al. The St Jude Medical Trifecta 
aortic pericardial valve: results from a global, multicenter, prospective 
clinical study. J Thorac Cardiovasc Surg. 2014;147(2):590–597.
 52. Wyss TR, Bigler M, Stalder M, et al. Absence of prosthesis-patient mis-
match with the new generation of Edwards stented aortic bioprosthesis. 
Interact Cardiovasc Thorac Surg. 2010;10(6):884–887; discussion 
887–888.
 53. Wendt D, Thielmann M, Plicht B, et al. The new St Jude Trifecta versus 
Carpentier-Edwards Perimount Magna and Magna Ease aortic biopros-
thesis: is there a hemodynamic superiority? J Thorac Cardiovasc Surg. 
2014;147(5):1553–1560.
 54. Bakhtiary F, Schiemann M, Dzemali O, et al. Stentless bioprostheses 
improve postoperative coronary flow more than stented prostheses 
after valve replacement for aortic stenosis. J Thorac Cardiovasc Surg. 
2006;131(4):883–888.
 55. Britten MB, Zeiher AM, Schächinger V. Microvascular dysfunction 
in angiographically normal or mildly diseased coronary arteries pre-
dicts adverse cardiovascular long-term outcome. Coron Artery Dis. 
2004;15(5):259–264.
 56. Hildick-Smith DJ, Shapiro LM. Coronary flow reserve improves after 
aortic valve replacement for aortic stenosis: an adenosine transthoracic 
echocardiography study. J Am Coll Cardiol. 2000;36(6):1889–1896.
 57. Bakhtiary F, Schiemann M, Dzemali O, et al. Impact of patient-prosthesis 
mismatch and aortic valve design on coronary flow reserve after aortic 
valve replacement. J Am Coll Cardiol. 2007;49(7):790–796.
 58. Pozzoli A, De Maat GE, Hillege HL, Boogaard JJ, Natour E, Mariani MA. 
Severe thrombocytopenia and its clinical impact after implant of the 
stentless Freedom Solo bioprosthesis. Ann Thorac Surg. 2013;96(5): 
1581–1586.
 59. Yerebakan C, Kaminski A, Westphal B, et al. Thrombocytopenia after 
aortic valve replacement with the Freedom Solo stentless bioprosthesis. 
Interact Cardiovasc Thorac Surg. 2008;7(4):616–620.
 60. Ravenni G, Celiento M, Ferrari G, et al. Reduction in platelet count 
after aortic valve replacement: comparison of three bioprostheses. 
J Heart Valve Dis. 2012;21(5):655–661.
 61. Selleng S, Malowsky B, Strobel U, et al. Early-onset and persisting 
thrombocytopenia in post-cardiac surgery patients is rarely due to 
heparin-induced thrombocytopenia, even when antibody tests are 
 positive. J Thromb Haemost. 2010;8(1):30–36.
 62. Tarzia V, Bottio T, Buratto E, Spiezia L, Simioni P, Gerosa G. Freedom 
solo stentless aortic valve: quantitative and qualitative assessment of 
thrombocytopenia. Ann Thorac Surg. 2011;92(5):1935.
 63. Khoo JP, Davies JE, Ang KL, Galiñanes M, Chin DT.  Differences in 
performance of five types of aortic valve prostheses:  haemodynamic 
assessment by dobutamine stress echocardiography. Heart. 2013;99(1): 
41–47.
 64. Adalbert R, Engelhardt JI, Siklós L. DL-Homocysteic acid application 
disrupts calcium homeostasis and induces degeneration of spinal motor 
neurons in vivo. Acta Neuropathol. 2002;103(5):428–436.
 65. Boldyrev AA. Molecular mechanisms of homocysteine toxicity. 
 Biochemistry (Mosc). 2009;74(6):589–598.
 66. Kobayashi J. Stentless aortic valve replacement: an update. Vasc Health 
Risk Manag. 2011;7:345–351.
 67. Borger MA, Prasongsukarn K, Armstrong S, Feindel CM, David TE. 
Stentless aortic valve reoperations: a surgical challenge. Ann Thorac 
Surg. 2007;84(3):737–743; discussion 743–744.
 68. Dvir D, Webb JG, Bleiziffer S, et al; Valve-in-Valve International Data 
Registry Investigators. Transcatheter aortic valve implantation in failed 
bioprosthetic surgical valves. JAMA. 2014;312(2):162–170.
 69. Mecozzi G, Milano AD, De Carlo M, et al. Intravascular hemolysis 
in patients with new-generation prosthetic heart valves: a prospective 
study. J Thorac Cardiovasc Surg. 2002;123(3):550–556.
 70. Desai ND, Merin O, Cohen GN, et al. Long-term results of aortic valve 
replacement with the St Jude Toronto stentless porcine valve. Ann 
Thorac Surg. 2004;78(6):2076–2083.
 71. Pavoni D, Badano LP, Ius F, et al. Limited long-term durability of 
the Cryolife O’Brien stentless porcine xenograft valve. Circulation. 
2007;116(Suppl 11):I307–I313.
 72. Carrel TP, Schoenhoff FS, Schmidli J, Stalder M, Eckstein FS, 
Englberger L. Deleterious outcome of No-React-treated stentless valved 
conduits after aortic root replacement: why were warnings ignored? 
J Thorac Cardiovasc Surg. 2008;136(1):52–57.
 73. Dellgren G, Eriksson MJ, Brodin LA, Rådegran K. Eleven years’ 
experience with the Biocor stentless aortic bioprosthesis: clinical and 
hemodynamic follow-up with long-term relative survival rate. Eur J 
Cardiothorac Surg. 2002;22(6):912–921.
 74. Grande KJ, Cochran RP, Reinhall PG, Kunzelman KS. Mechanisms 
of aortic valve incompetence: finite element modeling of aortic root 
dilatation. Ann Thorac Surg. 2000;69(6):1851–1857.
 75. Sripathi VC, Kumar RK, Balakrishnan KR. Further insights into 
normal aortic valve function: role of a compliant aortic root on 
leaflet opening and valve orifice area. Ann Thorac Surg. 2004;77(3): 
844–851.
